Kawabe Joji, Higashiyama Shigeaki, Sougawa Mitsuharu, Yoshida Atsushi, Kotani Kohei, Shiomi Susumu
Department of Nuclear Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.
CyberKnife Center, Osaka Medical College Mishima-Minami Hospital, Osaka, Japan.
Case Rep Endocrinol. 2017;2017:7956726. doi: 10.1155/2017/7956726. Epub 2017 Mar 15.
A woman in her 60s presented with a recurrent lymph node metastasis from a papillary thyroid carcinoma in the right parapharyngeal space. She had already undergone total thyroidectomy, five resections for cervical lymph node metastases, and right carotid rebuilding. Surgical resection of the current metastasis was impossible. I-radioiodine therapy (RIT) with 3.7 GBq I was not effective; therefore, stereotactic radiation therapy (SRT) using a CyberKnife radiotherapy system was scheduled. The prescription dose was 21 Gy, and a dose covering 95% of the planning target volume (PTV) in three fractions was administered. The PTV was 4,790 mm. Follow-up magnetic resonance imaging conducted 3 and 12 months after the SRT demonstrated a remarkable and gradual reduction of the recurrent lymph node metastasis in the right parapharyngeal space and no evidence of recurrence. For multidisciplinary therapy of unresectable and/or RIT unresponsive locoregional lymph node metastases and recurrences of DTC, SRT using the CyberKnife system should be considered.
一名60多岁的女性因右侧咽旁间隙甲状腺乳头状癌复发性淋巴结转移前来就诊。她已经接受了甲状腺全切除术、五次颈部淋巴结转移灶切除术以及右侧颈动脉重建术。目前无法对转移灶进行手术切除。给予3.7 GBq碘的碘-131放射碘治疗(RIT)无效;因此,计划使用射波刀放射治疗系统进行立体定向放射治疗(SRT)。处方剂量为21 Gy,分三次给予覆盖计划靶体积(PTV)95%的剂量。PTV为4790 mm³。SRT后3个月和12个月进行的随访磁共振成像显示,右侧咽旁间隙复发性淋巴结转移明显且逐渐缩小,无复发迹象。对于不可切除和/或对RIT无反应的分化型甲状腺癌局部区域淋巴结转移和复发的多学科治疗,应考虑使用射波刀系统进行SRT。